Clopidogrel in clinical practice for myocardial revascularisation: from the origins to the latest recommendations

Abstract

Ischaemic heart disease is a common cause of death and disability globally. Myocardial revascularisation is one of the most important components of the complex therapy of atherosclerosis. Clopidogrel has long been an attractive antiplatelet drug in clinical practice. Large amounts of evidence and data for P2Y12 platelet inhibitors support the use of clopidogrel in various clinical situations.The pharmacokinetic and pharmacodynamic features of the drug should be considered in everyday practice. Current guidelines clearly define the place and role of clopidogrel in the treatment of patients before and after revascularisation. This article focuses on various aspects of antiplatelet therapy, considering the patient-related risks, based on the European guidelines for the treatment of patients with acute and chronic coronary syndrome.Received 21 September 2021. Revised 16 October 2021. Accepted 18 October 2021.Funding: The study did not have sponsorship.Conflict of interest: Authors declare no conflict of interest.Contribution of the authors: The authors contributed equally to this article.